ERBB2 and breast carcinoma: It was approved by FDA on 11 March 2022 for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have previously received multiple lines of chemotherapy.